Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial

BACKGROUND: Solriamfetol is approved (US and EU) for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. OBJECTIVES: Evaluate solriamfetol safety/efficacy for EDS in Parkinson's disease (PD). METHODS: Phase 2, double‐blind, 4‐week, crossover trial: adults with PD and E...

Descripción completa

Detalles Bibliográficos
Autores principales: Videnovic, Aleksandar, Amara, Amy W., Comella, Cynthia, Schweitzer, Paula K., Emsellem, Helene, Liu, Kris, Sterkel, Amanda L., Gottwald, Mildred D., Steinerman, Joshua R., Jochelson, Philip, Zomorodi, Katie, Hauser, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596433/
https://www.ncbi.nlm.nih.gov/pubmed/34191352
http://dx.doi.org/10.1002/mds.28702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596433/
https://www.ncbi.nlm.nih.gov/pubmed/34191352
http://dx.doi.org/10.1002/mds.28702

Ejemplares similares